2017 American Transplant Congress
Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients.
Drugs are classified as highly variable when intra-patient coefficient of variation (CV%) is > 30%. Tacrolimus (TAC) is characterized as highly variable often without supporting…2017 American Transplant Congress
High Mortality in Transplant Recipients Associated with Coccidioidomycosis Derived from Organ Donors.
Purpose Coccidioidomycosis (CI) occurs in 4-9% of solid organ recipients in endemic areas, resulting in 30-63% mortality. CI can be transmitted directly via transplantation, but…2017 American Transplant Congress
Stability of Immune Phenotype, Alloreactive, and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.
David Geffen School of Medicine at UCLA, Los Angeles, CA
Purpose: This investigator-initiated study examines the impact of belatacept on T cell immune phenotype and function.Methods: 14 patients who had completed the study protocol were…2017 American Transplant Congress
Differential Effects of Immunosuppressive Drugs on DNA Methylation in T Cells.
Introduction The immune response after transplantation can be affected by DNA methylation – an epigenetic modification that regulates gene expression, including that of immune-related genes.…2017 American Transplant Congress
Kidney Recipients with 10 Year Belatacept-Treatment Display an Altered T Cell Subset Composition and Low Plasma Cytokine Levels Compared to Matched Patients with CNI-Based Immunosuppression.
Introduction/BackgroundMore than 10 years ago, Belatacept (Bela)-based immunosuppression was investigated in the BENEFIT trial of kidney transplantation (KTx) compared to CNI-based immunosuppression. Bela inhibits T…2017 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients: A Mate Kidney Analysis.
Nephrology, Internal Medicine, Allegheny General Hospital, Pittsburgh, PA
In the current era of powerful maintenance immunosuppression, it is unclear whether induction therapy positively adds to the outcomes in low immune risk kidney transplant…2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…2017 American Transplant Congress
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
University of Maryland School of Medicine, Baltimore, MD
Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.
Background: Hydroxychloroquine, also known as Plaquenil ( PLQ) is an antimalarial drug with immunomodulatory action. Recent studies have demonstrated a protective effect of PLQ in…
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 138
- Next Page »